ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Browse : By Sponsor : Industry : Daiichi Pharmaceuticals


Include trials that are no longer recruiting patients.

25 studies were found.
1.RecruitingCevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
Conditions: Hypopharyngeal Cancer; Laryngeal Cancer; lip and oral cavity cancer; metastatic squamous neck cancer with occult primary; Nasopharyngeal Cancer; ...
2.CompletedChemotherapy in Treating Patients Who Have Hematologic Cancer
Conditions: refractory chronic lymphocytic leukemia; recurrent adult acute myeloid leukemia; refractory anemia with excess blasts in transformation; ...
3.CompletedChemotherapy in Treating Patients With Prostate Cancer
Conditions: stage IV prostate cancer; recurrent prostate cancer
4.CompletedChemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer; Fallopian Tube Cancer; stage III ovarian epithelial cancer; ...
5.CompletedChemotherapy in Treating Women With Metastatic Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer
6.RecruitingDJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Condition: unspecified adult solid tumor, protocol specific
7.RecruitingDJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
Conditions: Colon Cancer; Rectal Cancer
8.CompletedDX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
Conditions: childhood Hodgkin's lymphoma; childhood brain tumor; childhood non-Hodgkin's lymphoma; childhood solid tumor
9.No longer recruitingDX-8951f in Treating Patients With Biliary Cancer
Conditions: localized gallbladder cancer; cholangiocarcinoma of the gallbladder; localized extrahepatic bile duct cancer; recurrent gallbladder cancer; ...
10.No longer recruitingDX-8951f in Treating Patients With Liver Cancer
Conditions: recurrent adult primary liver cancer; advanced adult primary liver cancer; localized resectable adult primary liver cancer; ...
11.No longer recruitingDX-8951f in Treating Patients With Metastatic Cancer of the Pancreas
Conditions: recurrent pancreatic cancer; duct cell adenocarcinoma of the pancreas; stage IV pancreatic cancer; adenocarcinoma of the pancreas
12.SuspendedDX-8951f in Treating Patients With Metastatic Stomach Cancer
Conditions: stage III gastric cancer; stage IV gastric cancer; recurrent gastric cancer; stage III esophageal cancer; stage IV esophageal cancer; ...
13.No longer recruitingDX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Conditions: stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer; recurrent non-small cell lung cancer
14.SuspendedDX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix
Conditions: stage III cervical cancer; stage IV cervical cancer; recurrent cervical cancer; cervical squamous cell carcinoma
15.No longer recruitingExatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma
Conditions: previously treated childhood rhabdomyosarcoma; recurrent childhood rhabdomyosarcoma
16.No longer recruitingExatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
Conditions: Ewing's family of tumors; childhood soft tissue sarcoma
17.No longer recruitingGemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
18.CompletedA Phase I Trial of Tecogalan sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.
Conditions: Sarcoma, Kaposi; HIV Infections
19.CompletedA Phase I Trial of Tecogalan sodium ( DS-4152 ) Administered as an Infusion Weekly x 4
Conditions: Sarcoma, Kaposi; HIV Infections
20.CompletedA Phase I Trial of Tecogalan sodium (DS-4152) Administered as an Infusion Every 21 Days
Conditions: Sarcoma, Kaposi; HIV Infections
21.RecruitingSoblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Condition: unspecified adult solid tumor, protocol specific
22.RecruitingSoblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Condition: adult soft tissue sarcoma
23.SuspendedSoblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions: stage IIIA non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; ...
24.RecruitingStudy of HGF via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia
Conditions: Arterial Occlusive Disease; Peripheral Vascular Disease; Ischemia
25.CompletedA Study of Tecogalan Sodium
Conditions: Sarcoma, Kaposi; HIV Infections

line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act